News

Fierce Pharma5h
Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout
Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...
pharmaphorum8h
Merck puts a price on its SpringWorks takeover bid
So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...
Merck KGaA (ETR:MRK) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
It looks like Merck KGaA (ETR:MRK) is about to go ex-dividend in the next 2 days. The ex-dividend date is two business days before a company's record date in most cases, which is the date on which the ...
M&A News: Merck KGaA to Buy SpringWorks for $3.5B to Boost Oncology Business
Germany’s Merck KGaA (DE:MRK) is in advanced talks to buy U.S.-based SpringWorks Therapeutics (SWTX) for roughly $3.5 billion, aiming to boost ...
STAT1h
Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...
Health Care Up After Merck Earnings -- Health Care Roundup
Healthcare companies rose after earnings from one Big Pharma company. Merck shares ticked up after the drug giant posted quarterly revenue ahead of Wall Street targets, lifted by growth in sales of ...
Merck Expects $200 Million Tariff Hit as Gardasil Sales Plunge
Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...